(BG) Bunge - Overview
Stock: Oilseeds, Grains, Vegetable Oils, Flours, Sugar
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.46% |
| Yield on Cost 5y | 5.37% |
| Yield CAGR 5y | 7.91% |
| Payout Consistency | 99.8% |
| Payout Ratio | 37.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.1% |
| Relative Tail Risk | -4.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.75 |
| Alpha | 62.16 |
| Character TTM | |
|---|---|
| Beta | 0.464 |
| Beta Downside | 0.438 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.82% |
| CAGR/Max DD | 0.22 |
Description: BG Bunge January 02, 2026
Bunge Limited (NYSE: BG) is a global agribusiness and food company organized into four operating segments: Agribusiness, Refined & Specialty Oils, Milling, and Sugar & Bioenergy. The Agribusiness arm trades and processes oilseeds (soy, rapeseed, canola, sunflower) and grains (wheat, corn), supplying animal-feed makers, millers and biofuel producers. Refined & Specialty Oils converts crude oils into packaged cooking oils, margarines, renewable-diesel feedstocks and specialty ingredients such as lecithin. The Milling segment produces wheat flours, corn-milling products and non-GMO blends for bakery and foodservice customers. Finally, the Sugar & Bioenergy segment generates sugar, ethanol and electricity from bagasse, linking agricultural output to renewable-energy markets.
Key recent metrics (FY 2023) show total revenue of roughly $58 billion, an adjusted EBITDA margin of about 9 %, and a net debt-to-EBITDA ratio near 2.1×, indicating moderate leverage. Bunge’s exposure to soybeans-its largest commodity-means earnings are highly sensitive to Brazil-U.S. soybean price spreads, which have averaged a + $0.30 per-bushel premium for Brazil over the United States in the past 12 months. The company’s renewable-diesel feedstock sales have grown ~ 15 % YoY, driven by tightening low-carbon fuel mandates in the EU and U.S.
Sector-wide drivers that will shape Bunge’s outlook include: (1) global grain-and-oilseed supply-demand imbalances amplified by climate-related yield volatility; (2) accelerating demand for plant-based protein and non-GMO ingredients, which lifts margins on higher-value oil-seed meals; and (3) regulatory pressure on sugar and ethanol markets, where carbon-credit pricing can materially affect bioenergy profitability. Bunge’s ability to capture value will depend on its logistics network efficiency (e.g., port turnaround times) and its success in expanding specialty-oil product lines.
For a data-rich, forward-looking assessment of BG’s valuation assumptions, you may find the ValueRay platform’s analyst toolkit useful for deeper research.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 816.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.44 > 1.0 |
| NWC/Revenue: 13.17% < 20% (prev 16.05%; Δ -2.88% < -1%) |
| CFO/TA 0.02 > 3% & CFO 834.0m > Net Income 816.0m |
| Net Debt (15.82b) to EBITDA (2.46b): 6.42 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.0m) vs 12m ago 39.66% < -2% |
| Gross Margin: 4.85% > 18% (prev 0.06%; Δ 478.3% > 0.5%) |
| Asset Turnover: 202.6% > 50% (prev 213.3%; Δ -10.70% > 0%) |
| Interest Coverage Ratio: 2.81 > 6 (EBITDA TTM 2.46b / Interest Expense TTM 628.0m) |
Altman Z'' 3.33
| A: 0.21 (Total Current Assets 24.39b - Total Current Liabilities 15.13b) / Total Assets 44.53b |
| B: 0.29 (Retained Earnings 13.05b / Total Assets 44.53b) |
| C: 0.05 (EBIT TTM 1.76b / Avg Total Assets 34.71b) |
| D: 0.64 (Book Value of Equity 17.37b / Total Liabilities 27.11b) |
| Altman-Z'' Score: 3.33 = A |
Beneish M -2.29
| DSRI: 1.07 (Receivables 3.87b/2.74b, Revenue 70.33b/53.11b) |
| GMI: 1.32 (GM 4.85% / 6.39%) |
| AQI: 1.27 (AQ_t 0.14 / AQ_t-1 0.11) |
| SGI: 1.32 (Revenue 70.33b / 53.11b) |
| TATA: -0.00 (NI 816.0m - CFO 834.0m) / TA 44.53b) |
| Beneish M-Score: -2.29 (Cap -4..+1) = BBB |
What is the price of BG shares?
Over the past week, the price has changed by +1.74%, over one month by +22.79%, over three months by +23.15% and over the past year by +73.06%.
Is BG a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 122.5 | 5.7% |
| Analysts Target Price | 122.5 | 5.7% |
| ValueRay Target Price | 136.9 | 18.1% |
BG Fundamental Data Overview February 07, 2026
P/E Forward = 13.5318
P/S = 0.3133
P/B = 1.3051
P/EG = 1.7053
Revenue TTM = 70.33b USD
EBIT TTM = 1.76b USD
EBITDA TTM = 2.46b USD
Long Term Debt = 8.83b USD (from longTermDebt, last quarter)
Short Term Debt = 5.93b USD (from shortTermDebt, last quarter)
Debt = 16.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.82b USD (from netDebt column, last quarter)
Enterprise Value = 37.85b USD (22.03b + Debt 16.95b - CCE 1.14b)
Interest Coverage Ratio = 2.81 (Ebit TTM 1.76b / Interest Expense TTM 628.0m)
EV/FCF = 127.9x (Enterprise Value 37.85b / FCF TTM 296.0m)
FCF Yield = 0.78% (FCF TTM 296.0m / Enterprise Value 37.85b)
FCF Margin = 0.42% (FCF TTM 296.0m / Revenue TTM 70.33b)
Net Margin = 1.16% (Net Income TTM 816.0m / Revenue TTM 70.33b)
Gross Margin = 4.85% ((Revenue TTM 70.33b - Cost of Revenue TTM 66.92b) / Revenue TTM)
Gross Margin QoQ = 4.25% (prev 4.80%)
Tobins Q-Ratio = 0.85 (Enterprise Value 37.85b / Total Assets 44.53b)
Interest Expense / Debt = 1.27% (Interest Expense 216.0m / Debt 16.95b)
Taxrate = 25.40% (288.0m / 1.13b)
NOPAT = 1.31b (EBIT 1.76b * (1 - 25.40%))
Current Ratio = 1.61 (Total Current Assets 24.39b / Total Current Liabilities 15.13b)
Debt / Equity = 0.98 (Debt 16.95b / totalStockholderEquity, last quarter 17.37b)
Debt / EBITDA = 6.42 (Net Debt 15.82b / EBITDA 2.46b)
Debt / FCF = 53.44 (Net Debt 15.82b / FCF TTM 296.0m)
Total Stockholder Equity = 13.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.35% (Net Income 816.0m / Total Assets 44.53b)
RoE = 5.98% (Net Income TTM 816.0m / Total Stockholder Equity 13.65b)
RoCE = 7.84% (EBIT 1.76b / Capital Employed (Equity 13.65b + L.T.Debt 8.83b))
RoIC = 5.53% (NOPAT 1.31b / Invested Capital 23.78b)
WACC = 4.73% (E(22.03b)/V(38.98b) * Re(7.63%) + D(16.95b)/V(38.98b) * Rd(1.27%) * (1-Tc(0.25)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 15.18%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈387.2m ; Y1≈254.2m ; Y5≈116.0m
Fair Price DCF = N/A (negative equity: EV 3.70b - Net Debt 15.82b = -12.12b; debt exceeds intrinsic value)
EPS Correlation: -72.81 | EPS CAGR: -18.37% | SUE: 0.23 | # QB: 0
Revenue Correlation: 1.23 | Revenue CAGR: 11.35% | SUE: 2.66 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.05 | Chg30d=-0.833 | Revisions Net=+2 | Analysts=6
EPS current Year (2026-12-31): EPS=8.04 | Chg30d=-0.896 | Revisions Net=-1 | Growth EPS=+6.2% | Growth Revenue=+29.1%
EPS next Year (2027-12-31): EPS=9.97 | Chg30d=-0.258 | Revisions Net=+1 | Growth EPS=+24.0% | Growth Revenue=+3.0%